Background Substantial concerns have been raised about the neuropsychiatric safety of the smoking cessation medications varenicline and bupropion. Their effi cacy relative to nicotine patch largely relies on indirect comparisons, and there is limited information on safety and effi cacy in smokers with psychiatric disorders. We compared the relative neuropsychiatric safety risk and effi cacy of varenicline and bupropion with nicotine patch and placebo in smokers with and without psychiatric disorders.
Introduction
The prescription medications varenicline and bupropion have been shown to substantially improve smokers' chances of stopping long term in many randomised trials and real-world observational studies. 1 However, substantial concerns have been raised about their safety, particularly with regard to neuropsychiatric adverse events such as suicidality and aggression. 2 Meta-analyses of randomised trials and large comparative observational studies have not supported these safety concerns, but before that information became available the US Food and Drug Administration (FDA) required the makers of these medications to conduct a suffi ciently large randomised trial to provide greater clarity on their potential safety risks. 3 Additionally, the smoking cessation effi cacy of these medications relative to each other and to nicotine replacement therapy, especially in smokers with psychiatric disorders, remains uncertain, depending largely on indirect comparisons and a limited number of studies with relatively small sample sizes. 4 The present study sought to address these issues with a very large double-blind, triple-dummy, active-controlled and placebo-controlled, randomised trial in smokers with and without a psychiatric disorder. The issue is of crucial importance because of the urgency surrounding smoking cessation, particularly for smokers with respiratory, cardiovascular, or other smoking-related diseases, and the need to be able to provide maximum
Research in context
Evidence before this study We searched PubMed, Cochrane Database of Systematic Reviews, and the websites of the US Food and Drug Administration (FDA) and European Medicines Agency for relevant reports published up to March 26, 2016 , and reviewed the reference lists from these documents. There were no language restrictions and the search terms included "varenicline", "bupropion", "nicotine replacement therapy", "safety", "adverse events", and "suicide". Case reports and analyses of post-marketing pharmacovigilance data from Europe, the USA, and other countries detected a possible signal that varenicline use might be associated with neuropsychiatric adverse events, a concern that was eventually extended to use of bupropion. As a result, the FDA issued a post-marketing requirement to the makers of varenicline and bupropion to do a randomised controlled trial to assess the risk of serious neuropsychiatric adverse events.
By contrast, studies by various authors with a variety of control groups, in a broad range of study populations-some with very large sample sizes-did not detect any signifi cant increase in neuropsychiatric adverse events in smokers prescribed varenicline or bupropion compared with nicotine replacement therapy or placebo. Although the results of these controlled studies consistently showed varenicline and bupropion to be associated with no greater incidence of serious neuropsychiatric adverse events than active or placebo comparators, some of the studies excluded smokers with psychiatric illness, a group who smoke a large proportion of the cigarettes consumed worldwide, and who might be more vulnerable to neuropsychiatric adverse events.
From the smoking cessation effi cacy perspective, most data on the comparative effi cacy of varenicline versus nicotine replacement therapy-such as those summarised in Cochrane network meta-analyses fi nding varenicline superior to single formulation nicotine replacement therapy-rely on indirect comparisons. A recent open-label trial comparing varenicline with single formulation and combination nicotine replacement therapy did not detect signifi cant diff erences across the treatments at 26 weeks. No previous studies have compared the smoking cessation effi cacy of the three fi rst-line smoking cessation aids head-to-head in smokers, and none have done so in smokers with current or past psychiatric disorders.
Added value of this study
This study addresses the need for a prospective study of adequate size and rigour to assess the potential for varenicline and bupropion to cause serious neuropsychiatric adverse events. The fi ndings show that it is highly unlikely that varenicline and bupropion contribute to neuropsychiatric adverse events of moderate-to-severe intensity at a rate above 1·5% in smokers without a psychiatric disorder and above 4% in smokers with such disorders. The results are also consistent with no increase in the incidence of these events. The study also provides the fi rst defi nitive evidence on the relative eff ectiveness of the diff erent smoking cessation medications in the special population of smokers with psychiatric disorders. The fact that the odds ratios for effi cacy did not diff er as a function of psychiatric status is crucial new information when it comes to treating this population who smoke at rates two to three times that of the general population and who are disproportionately aff ected by smoking-related illness. The fi ndings will be used by medicines regulators, clinicians, and smokers to make an informed choice about life-preserving treatments.
Implications of all the available evidence
The fi ndings from this study, the largest of its kind, together with those from meta-analyses of previous randomised controlled trials and very large observational cohort studies, make it highly unlikely that varenicline or bupropion increase the risk of moderate-to-severe neuropsychiatric adverse events in smokers without psychiatric disorders. The evidence from all available sources is less clear in smokers with psychiatric disorders; however, if there is an increased risk in this group, this is expected to be small. The available evidence, substantially boosted by this study, clearly shows the effi cacy of all three fi rst-line smoking cessation medications with varenicline having the largest eff ect, in smokers with and without psychiatric disorders. support for smokers to help them achieve abstinence based on an accurate risk-benefi t analysis.
Clinical practice guidelines recommend that the most eff ective way for moderate-to-heavy smokers to quit is by combining a smoking cessation medication with counselling. 4 However, smoking cessation support is underused, 5 in part due to smokers' and clinicians' concerns that the medications might not be safe, especially regarding the risk of developing serious neuropsychiatric symptoms-a concern that is refl ected in the package insert for two of the fi rst-line agents, varenicline and bupropion, as warnings or precautions in most countries and as boxed warnings in some countries including the USA. Given the high risk of smokinginduced illness and death, the reluctance of clinicians to prescribe the most eff ective smoking cessation medications places many smokers at further risk.
Concerns about neuropsychiatric safety of varenicline and bupropion arose from case reports, 6,7 post-marketing surveillance analyses, 2,8 and the initial dearth of studies in smokers with psychiatric disorders who are most likely to report such events. 9 However, studies with active and placebo comparators published over the past 4 years report that use of these medications did not increase neuropsychiatric symptom risk. Randomised, placebocontrolled trials of varenicline in smokers with various psychiatric disorders 10, 11 identifi ed no neuropsychiatric safety signals and no worsening of the underlying psychiatric condition. Independent meta-analyses of these trials have reported no evidence of an association between varenicline 12, 13 or bupropion 14 and neuropsychiatric adverse events. Observational studies examining severe outcomes (eg, suicidal behaviour, admission to hospital) in large cohorts of smokers, many of whom had comorbid psychiatric disorders, have not found a heightened risk of serious neuropsychiatric adverse events for varenicline 9, 15 or bupropion. 16 However, these studies all have limitations. 3 For example, most studies included in the meta-analyses did not prospectively and systematically probe for all serious neuropsychiatric adverse events of interest, and the more recent observational studies might suff er from channelling bias where sicker patients were shunted away from using the non-nicotine smoking cessation aids because of concerns about their side-eff ects. 3 Thus, there remains a need to determine the neuropsychiatric safety profi le of varenicline and bupropion in a randomised, double-blind, active-controlled and placebocontrolled trial in smokers with and without psychiatric disorders that systematically probes for these neuropsychiatric adverse events while participants are on-treatment and off -treatment during and following their smoking cessation attempt.
In addition to safety issues, the smoking cessation effi cacy of the non-nicotine medications relative to nicotine replacement therapy, which also plays a role in determining their benefi t-risk ratio, has also not been well studied in head-to-head trials, particularly in smokers with psychiatric disorders. A network meta-analysis done by the independent Cochrane Database of Systematic Reviews recommended that direct comparisons among single and combination form ulations of nicotine replacement therapy with varenicline would be valuable. 1 A recent open-label trial in lighter smokers 17 further highlights the need for double-blind, placebo-controlled, head-to-head comparisons as evidenced by that study's results being inconsistent with previous fi ndings of meta-analyses that varenicline was more effi cacious than single formulation nicotine replacement therapy. 1 It is also not known whether the relative effi cacies of these fi rst-line smoking cessation medications diff er as a function of a smoker's psychiatric history, because no previous comparative effi cacy trials directly compared the medications in smokers with and without psychiatric disorders.
With these gaps in the literature in mind, herein we describe the results of the largest trial of pharmacotherapy for smoking cessation done to date, with the objective of comparing the relative safety and effi cacy of these medications in smokers with and without psychiatric disorders. The study was requested by, and designed in consultation with, the FDA. The study is also a postauthorisation safety study in the European Union.
Methods

Study design and participants
The Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) was a multinational, multicentre, randomised, double-blind, placebocontrolled and active-controlled trial, done at 140 centres in 16 countries across fi ve continents (appendix). Study sites included clinical trial centres, academic centres, and outpatient clinics treating patients with and without psychiatric disorders.
Eligible participants were smokers, aged 18-75 years, with and without prespecifi ed psychiatric diagnoses per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), 18 who smoked an average of ten or more cigarettes per day during the previous year, had an exhaled carbon monoxide concentration greater than 10 parts per million (ppm) at screening, and who were motivated to stop smoking as evidenced by signing the informed consent before trial enrolment specifying that a target quit date would be set. Potential participants were recruited from the investigators' own clinics; through newspaper, radio, and television advertising; and fl iers and posters. Participants were included in the psychiatric cohort if they met DSM-IV-TR diagnostic criteria for mood disorders including major depressive disorder or bipolar disorder; anxiety disorders including panic disorder, with or without agoraphobia, post-traumatic stress disorder, obsessive-compulsive disorder, social phobia, and generalised anxiety disorder; psychotic disorders including schizophrenia and schizoaff ective disorders; 
Lifetime suicide-related history from C-SSRS or borderline personality disorder. Those with qualifying primary psychiatric disorders were not excluded for other psychiatric comorbidities, but those secondary allowable diagnoses were also prespecifi ed and excluded destabilising psychiatric conditions such as alcohol and other drug use disorders within the previous 12 months. Participants had to be considered clinically stable for inclusion (ie, no exacerbations of their condition in the preceding 6 months; on stable treatment for at least 3 months, with no treatment change anticipated during the study), and considered by the investigator not to be at high risk of self-injury or suicidal behaviour as gauged by participants' responses on the Suicide Behaviors Questionnaire-Revised, 19 or Columbia-Suicide Severity Rating Scale (C-SSRS), 20 both administered at screening, and, if necessary, professional mental health assessment. Participants in the non-psychiatric cohort had no confi rmed history of DSM-IV-TR Axis I or II disorders.
Complete inclusion and exclusion criteria are described in the appendix. Written consent forms and study procedures were approved by the institutional review boards or ethics committees at participating institutions. The study adhered to the Declaration of Helsinki 21 and the International Conference on Harmonisation Good Clinical Practice Guidelines. 22 An independent Data Monitoring Committee reviewed safety data at prespecifi ed timepoints to ensure participant safety and sample size adequacy. All participants signed informed consent and received fi nancial compensation for study participation time and travel expenses as per standards set at each trial site.
Randomisation and masking
Eligible participants were stratifi ed into a non-psychiatric cohort and four sub-cohorts in the psychiatric cohort based on their psychiatric primary diagnosis, and by site product kit codes did not allow deciphering of randomised treatment or block size. As such, participants, investigators, and research personnel were masked to treatment assignments.
Procedures
Participants set a target quit date 1 week after randomisation to coincide with the end of the titration for varenicline and bupropion and the initiation of nicotine patch treatment. Smoking cessation counselling of at most 10 min based on Agency for Healthcare Research and Quality guidelines 4 was given at each clinic visit. Participants were encouraged to complete all study visits even if treatment was discontinued. At each study visit, pill and patch counts were done and documented to measure medication compliance. Compliance was defi ned as having any (partial or full) daily dose of study drug for 80% of the planned treatment period (ie, a minimum of 68 days). Using this metric, overall treatment compliance was about 80% across the four treatment conditions. Tobacco and nicotine use were assessed with a structured questionnaire at all clinic visits and telephone contacts. All clinic visits included expired air carbon monoxide measurement. Emergence of adverse events
was assessed with open-ended questions, direct observation, and a semi-structured Neuropsychiatric Adverse Events Interview (NAEI) done at all study visits by trained interviewers to fully capture neuropsychiatric adverse events of interest (appendix). The NAEI comprises 25 questions to probe for psychiatric symptoms during a clinical trial; 10 positive responses were considered possible neuropsychiatric adverse events that were assessed further by the trained interviewer by inquiring about each symptom's frequency, duration, and severity. General or psychiatric adverse events that met FDA requirements for serious adverse events-eg, resulting in death, admission to hospital, substantial disability, or life-threatening events-were classifi ed accordingly. Additionally, investigators were instructed to assess whether positive responses on the C-SSRS, 20 and any proxy reports, such as from participants' family members or physicians, were neuropsychiatric adverse events.
Psychiatric diagnosis was assessed at screening with the Structured Clinical Interviews for DSM-IV-TR Axis I and II Disorders (SCID-I and SCID-II). 23, 24 Aspects of psychiatric symptom severity were assessed at baseline and all visits with the C-SSRS, 20 and Hospital Anxiety and Depression Scale (HADS). 25 Participants who reported a severe neuropsychiatric adverse event, were considered to be at increased suicide risk, or had any substantial worsening of their psychiatric condition, underwent a psychiatric evaluation or risk assessment at that visit by a mental health professional who made specifi c treatment or intervention recommendations, including whether the participant could continue the study. The Fagerström Test for Cigarette Dependence (FTCD) 26 was used to assess cigarette dependence severity at baseline.
Outcomes
The primary endpoint was a composite measure based on post-marketing reports of neuropsychiatric adverse events in smokers taking varenicline and bupropion. Feeling abnormal ‡ 0 0 0 0 0 1 (0·1%) 0 0 Data are n (%), unless otherwise stated. Based on least squares means analysis, point estimate, and its 95% CI. Estimated risk diff erence is based on a General Linear Model with terms treatment, cohort, region, and treatment by cohort interaction. Region uses two-level classifi cation (USA, non-USA). Adverse events reported during treatment and 30 days or less after last dose. Participants are counted only once per each row, even if they have reported multiple events; participants can be counted in multiple rows. RD=risk diff erence. *All-treated population. †One additional participant in the nicotine patch group (psychiatric cohort) who reported moderate suicidal ideation (serious adverse events) was identifi ed after the clinical database was locked; consequently, the participant was not included in the analysis of the primary study endpoint. ‡Severe intensity adverse events. §Moderate and severe intensity adverse event. ¶Serious adverse events were: non-psychiatric cohort: bupropion, suicide attempt (1); nicotine patch, suicide attempt (1), panic (1); placebo, suicidal ideation (2), completed suicide (1); psychiatric cohort: varenicline, suicidal ideation (2), depression (1), auditory hallucination (1), exacerbation of bipolar I disorder (1), anxiety plus self-injurious behaviour (1); bupropion, suicide attempt plus schizoaff ective disorder (1), exacerbations of bipolar I disorder (2) and bipolar II disorder (1), emotional disorder plus neuropsychiatric symptoms (1); nicotine patch, anxiety (2), depression (1); placebo, suicide attempt (1), suicidal ideation (1), aggression (1). **Interventions include: psychotropic medication, psychotherapy, counselling, and admission to hospital. usual daily functioning), moderate (some interference with functioning), or severe (substantial interference). Prespecifi ed severity criteria for the primary neuropsychiatric adverse event endpoint required adverse events for the four components expected to be reported more commonly (anxiety, depression, feeling abnormal, or hostility) to be rated as severe. Neuropsychiatric adverse events in the remaining 12 categories (agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, behaviour, or completed suicide) met severity criteria when rated as either moderate or severe. A simplifi ed scheme of the primary composite safety endpoint is shown in the appendix. Secondary safety endpoints included the subset of all neuropsychiatric adverse events that were rated severe and the occurrence of each of the individual components. Other safety assessments included psychiatric rating scales (see below), all adverse events, vital signs, and select laboratory values. Cardiovascular safety data will be reported separately, after completion of the 28-week nontreatment extension phase.
The primary effi cacy endpoint for smoking cessation was the continuous abstinence rate for weeks 9-12. Participants were considered abstinent who selfreported tobacco abstinence throughout the period in conjunction with no exhaled carbon monoxide concentration greater than 10 ppm. Missing self-reports before week 12 were imputed via a backward carry method (missing at week 12 was deemed a smoker). Missing carbon monoxide measurements were imputed as less than 10 ppm, but a sensitivity analysis was also done imputing missing values as smoking. In accordance with recommended practice, 27 participants who were lost to follow-up were considered to be smokers. The pre-designated secondary effi cacy endpoint was carbon monoxide-confi rmed continuous abstinence for weeks 9-24 defi ned similarly. 7-daypoint-prevalence of abstinence at all visits or contacts was also a prespecifi ed outcome.
Statistical analysis
The sample for this study was driven by a requirement to estimate the size of increase in the rate of neuropsychiatric adverse events relative to the placebo group with a prespecifi ed level of precision. Based on pooled data from previous randomised controlled trials, 28 the underlying placebo rates for neuropsychiatric adverse events in the non-psychiatric cohort and psychiatric cohort were postulated to be 3·5% and 7·0%, respectively. A sample size of 2000 per treatment group was determined to be suffi cient to estimate a 75% increase in neuropsychiatric adverse event rate within +1·59% or -1·59%. The sample size is also suffi cient to detect a two-fold increase in the odds of abstinence rate in the placebo group.
Point and interval estimates of risk diff erences (RDs; ie, diff erences in percentages of incidence of neuropsychiatric adverse events), were obtained using generalised linear regression with terms to account for treatment, cohort (non-psychiatric cohort and psychiatric cohort), region (reduced to two regions: USA and non-USA), and interactions. Diff erences were considered signifi cant if their associated 95% CIs were entirely below or above zero. Logistic regression analysis was used for the analysis of abstinence endpoints. The estimates of odds ratios (ORs) and corresponding 95% CIs were obtained via linear contrasts.
All participants randomised to study medications comprised the population for effi cacy analyses and participants treated with study medications comprised the population for analysis of safety. The varenicline and bupropion comparisons versus placebo were prespecifi ed as primary; all other treatment comparisons were deemed Data are n or n (%). *All-treated population. †Suicidal behaviour (most severe for each participant with positive answers on the C-SSRS). ‡During treatment: non-psychiatric cohort: nicotine patch, suicide attempt (1); placebo, completed suicide (1); psychiatric cohort: bupropion, suicide attempt (1); placebo, suicide attempt (2) . §Completed suicide. ¶During follow-up: non-psychiatric cohort: bupropion, suicide attempt (1); psychiatric cohort: varenicline, suicide attempt (1); nicotine patch, aborted attempt (1); placebo, aborted attempt (1). secondary. No adjustments for multiplicity of testing were made. The trial is registered at ClinicalTrials.gov (number NCT01456936) and is now closed.
Role of the funding source
The study is a post-marketing requirement in the USA for Pfi zer and GlaxoSmithKline. As such, the study was designed by sponsor employees (with input from AK, LSA, DL, and CR) and academic authors (RMA, and also with input from NLB, AEE, and RW). The lead academic (corresponding) author prepared the initial draft of the manuscript. All authors were involved with the acquisition, analysis, or interpretation of the data and critically revised the manuscript for important intellectual content. The lead academic author had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. All authors assume responsibility for the completeness and integrity of the data and for the fi delity of the study to the protocol and statistical analysis plan.
Results
Between Nov 30, 2011, and Jan 13, 2015, 11 186 smokers were screened, of which 8144 (73%) were randomly assigned to a non-psychiatric cohort (n=4028) and a psychiatric cohort (n=4116; fi gures 1 and 2). Among treated participants in the non-psychiatric cohort (n=3984) and psychiatric cohort (n=4074), 3145 (79%) and 3023 (74%), respectively, completed treatment, and 3124 (78%) and 3169 (78%) participants, respectively, completed the study (fi gures 1 and 2). Reasons for discontinuations were similar across cohorts and treatment groups. Baseline demographic, smoking, and psychiatric characteristics for all treated participants are presented in table 1. Overall the study population included 3549 (44%) men, had an average age of 46·5 years, and 6584 (82%) participants of white race and ethnicity. Most participants came from the USA (4207 [52%]). Participants smoked an average of 21 cigarettes per day with an average FTCD of 5·8 and 6647 (82%) participants had made at least one previous attempt to quit. The treatment groups had similar baseline characteristics within cohorts, but smokers in the psychiatric cohort were more likely to be female, reside in the USA, and have higher FTCD scores ( 1377 (34%) participants had a history of suicidal ideation and 514 (13%) participants had a history of suicidal behaviour based on the C-SSRS. The overall incidence of the neuropsychiatric adverse event endpoint was similar across the four treatment groups: varenicline 4·0% (80 of 2016 participants), bupropion 4·5% (90 of 2006 participants), nicotine patch 3·9% (78 of 2022 participants), and placebo 3·7% (74 of 2014 participants). There were more neuropsychiatric adverse events in the psychiatric cohort (5·8%, 238 of 4074 participants) than the non-psychiatric cohort (2·1%, 84 of 3984 participants; p<0·0001 for the cohort eff ect; table 2). There was a treatment by cohort interaction (p=0·0652), so analyses of neuropsychiatric adverse events by treatment assignment are presented for each cohort separately. For the non-psychiatric cohort, the risk for the composite safety endpoint was lower for participants assigned to varenicline than those assigned to placebo (RD −1·28, 95% CI −2·40 to −0·15), although there was no signifi cant diff erence in neuropsychiatric adverse events in those assigned to bupropion versus placebo (RD -0·08, -1·37 to 1·21). Diff erences between varenicline and nicotine patch and between bupropion and nicotine patch were also not signifi cant in the nonpsychiatric cohort. In the psychiatric cohort, there were no signifi cant pairwise treatment diff erences (95% CIs included zero).
A third or fewer of the participants (between two and fi ve per treatment group in the non-psychiatric cohort and ten and 17 in the psychiatric cohort) who met the primary safety endpoint reported more than one neuropsychiatric adverse event (appendix). Of the participants reporting the primary neuropsychiatric endpoint, the percentage of those reporting neuropsychiatric adverse events that were severe, met serious adverse event criteria, or led to treatment discontinuations or interventions (ie, the clinically most signifi cant events), was lower in the non-psychiatric cohort than the psychiatric cohort and was similar across treatment groups (table 2) .
The number of participants reporting suicidal ideation or behaviour on the C-SSRS was greater in the psychiatric cohort than in the non-psychiatric cohort and similar across treatment groups (table 3) . There was one completed suicide in the study in a placebo-treated participant in the non-psychiatric cohort. The average total HADS score improved from baseline through the treatment phase by about 2 points in the non-psychiatric cohort and 3 points in the psychiatric cohort, an eff ect that was similar across the treatment groups (appendix). Table 4 lists all adverse events (mild, moderate, and severe) in the Psychiatric Disorder MedDRA category occurring in at least 1% of any treatment group in either cohort, irrespective of whether they met the criteria for the primary neuropsychiatric adverse event endpoint. Those in the psychiatric cohort were more likely to report neuropsychiatric adverse events of all types than those in the non-psychiatric cohort. The profi le of adverse events exhibited (eg, abnormal dreams more common for varenicline and nicotine patch compared with placebo) was consistent with previous reports. Incidences of general adverse events, serious adverse events, deaths, treatment discontinuations, and adverse events observed in at least 5% of participants are summarised in the appendix. Overall, the treatments were well tolerated. In brief, across cohorts, the most frequent adverse events by treatment group were nausea (varenicline, 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), abnormal dreams (nicotine patch, 12% [251 of 2022 participants]), and headache (placebo, 10% [199 of 2014 participants]).
As specifi ed in the study protocol, an analysis was undertaken to assess whether treatment effi cacy varied between the non-psychiatric cohort and psychiatric cohort, and although the abstinence rates are lower in the psychiatric cohort versus non-psychiatric cohort (fi gure 3), no evidence was found for an interaction (p=0·6237). The continuous abstinence rates for weeks 9-12 and 9-24 by treatment and the ORs for all pairwise comparisons are presented for the combined sample as well as for the two cohorts in fi gure 3. Varenicline showed superior effi cacy to placebo and to both nicotine patch and bupropion at end of treatment (weeks 9-12) and follow-up (weeks 9-24). Bupropion showed similar effi cacy to nicotine patch and both showed superior effi cacy versus placebo. Imputing missing carbon monoxide measurements that occurred in 72 participants self-reporting continuous abstinence during weeks 9-24 as smoking did not signifi cantly aff ect the results (appendix). 7-day point prevalence of abstinence for weeks 1-24 show results consistent with the continuous abstinence rates (appendix).
Discussion
Our large multinational trial did not show a signifi cant increase in rates of moderate-to-severe neuropsychiatric adverse events with either varenicline or bupropion relative to nicotine patch or placebo in those with or without psychiatric disorders. We did not fi nd treatmentassociated changes on validated, longitudinal assess ments of suicidality using the C-SSRS, of mood and anxiety symptoms with the HADS, or conventional assessments of neuropsychiatric adverse events including treatment discontinuation. Varenicline showed superior effi cacy to bupropion and nicotine patch in both cohorts, whereas bupropion had similar effi cacy to nicotine patch with both showing superior effi cacy to placebo in both cohorts.
Interpreting the CIs for the primary outcome measure, our fi ndings make it highly unlikely that varenicline or bupropion increase moderate-to-severe neuropsychiatric adverse events by more than 1·5 percentage points in smokers without psychiatric disorders, and by 4 percentage points in smokers with psychiatric disorders based on the upper bounds of the 95% CIs. They are also consistent with there being no increase in neuropsychiatric adverse events in either population of smokers.
The study detected about a 4 percentage point signifi cant diff erence in the rate of neuropsychiatric adverse events between the psychiatric and nonpsychiatric cohorts. Moreover, the observed incidence was close to the postulated values-about 2% in the nonpsychiatric cohort and 6% in the psychiatric cohort-so it seems unlikely that failure to detect medication eff ects was attributable to lack of sensitivity of the measures or selection of smokers with unusually good mental health.
These results add substantially to those of the previous meta-analyses of randomised controlled trials [12] [13] [14] and observational studies, 9, 15, 16, 29 using a rigorous experimental design and very detailed proactive assessment of treatment-emergent and post-treatment neuropsychiatric symptoms, thereby addressing limitations of the previous studies. Therefore, they provide important new information on which regulators, prescribers, and smokers can make an informed choice when deciding how best to address nicotine dependence.
Our fi ndings show for the fi rst time that the effi cacy of the medications in terms of ORs is similar for smokers with or without psychiatric disorders. Smokers in the psychiatric cohort achieved lower abstinence rates than those in the non-psychiatric cohort, so the absolute eff ect size was smaller in those with psychiatric disorders than those without, but it was still substantial. Moreover, inspection of the 7-day point prevalence of abstinence curves reveals a similar recruitment to abstinence eff ect previously described in non-psychiatrically ill smokers with varenicline. Further analyses will be helpful in assessing whether there is any evidence of diff erential eff ectiveness as a function of the severity of the psychiatric disorder or diagnostic category.
This study provides the fi rst evidence of comparative effi cacy between the three main pharmacological treatments to aid smoking cessation in a double-blind and triple-dummy trial. The size of the diff erences is similar to what was predicted from the Cochrane network meta-analysis. 1 The fact that this study was done in many centres in countries with widely diff erent attitudes regarding tobacco use, confi rms the generalisability of these conclusions across cultures.
Our results appear to diff er from a recent open-label study that compared varenicline with combination nicotine replacement therapy (nicotine patch plus lozenge) and single formulation nicotine replacement therapy (nicotine patch). 17 On the most comparable outcome measure of prolonged abstinence at 26 weeks, that study found an OR of 1·1, but with a relatively small sample size, the 95% CI (0·7 to 1·7) overlapped with the point estimate found in the present study (1·52) and with the estimate from the Cochrane network meta-analysis (1·57).
The present study has several limitations. First, we included smokers with psychiatric disorders who were stable and treated or who had previous psychiatric conditions (eg, major depressive disorder) that were in remission. Thus, these selection eff ects might have aff ected the fi ndings, and our results might not generalise to those with untreated or symptomatically unstable psychiatric illness. Similarly, we restricted the scope of the psychiatric cohort to smokers in four major disease categories-mood, anxiety, psychotic, and borderline personality disorders-and excluded participants with other current substance use disorders or who were at imminent risk for suicide, further limiting generalisability. Second, the 24-week duration of the study and frequent monitoring might not mirror a real-world smoking cessation attempt. Third, although this is the largest double-blind, placebo-controlled safety and effi cacy trial of pharmacotherapy for smoking cessation done to date, some of the sub-cohorts in the psychiatric cohort are smaller than others, our study was not powered to detect diff erences in rare events such as completed suicides, nor can we rule out, based on the upper bound 95% CIs, an increase of serious neuropsychiatric adverse events as defi ned of up to 4% in the psychiatric cohort. Fourth, we recruited individuals who smoked, on average, at least ten cigarettes per day and who were moderately nicotine dependent. Thus, our fi ndings might not generalise to lighter, less severely dependent smokers. Fifth, our analyses did not consider the potential moderating eff ects of sex, dependence severity, and depression or anxiety symptoms between the cohorts, which were not prespecifi ed in our statistical analysis plan, but will be considered along with other predictor variables in subsequent publications. Finally, attrition occurred across all treatment groups between both cohorts, and missing data could have aff ected outcomes. These limitations aside, the lack of any signal for serious neuropsychiatric adverse events in this and other randomly controlled trials, [10] [11] [12] [13] [14] 30 combined with the growing number of studies fi nding no such association in large cohorts of smokers with or without psychiatric disorders, 9, 15, 16, 29 makes it improbable that use of these medications in psychiatrically stable smokers is causally associated with a heightened neuropsychiatric safety risk.
In summary, in the context of evidence from clinical trials and observational cohort studies, this large, multinational trial provides further evidence that varenicline and bupropion can be used safely by psychiatrically stable smokers. Although varenicline appears to be the most eff ective single pharmacotherapy available, all of the fi rst-line medications-varenicline, bupropion, and nicotine patch-are effi cacious compared with placebo.
